Maharashtra state-owned Haffkine Biopharma on June 2 said it plans to produce 22.8 crore (228 million) doses of Covaxin in a year.
Mumbai-based Haffkine will be manufacturing Covaxin under a technology transfer arrangement with Bharat Biotech.
Haffkine has so far been provided with Rs 65 crore grant by the Centre and Rs 94 crore from the Government of Maharashtra, which will be utilised for setting up a BSL-3 facility for manufacturing and acquiring raw materials.
“We have been given a timeline of eight months and the work is being executed on a war footing,” said Dr Sandeep Rathod, Managing Director of Haffkine BioPharma.
“The vaccine production process involves two stages – drug substance and final drug product. For the production of drug substance we need to build a Bio Safety Level 3 (BSL 3) facility, while Haffkine already has the Fill Finish facility,” Rathod said.
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…
https://youtu.be/mdl3AFFFcuk?si=i2cYzTX7WJ-z6wRp Does Chyawanprash Help in Cough & Cold? Exploring Its Benefits and Efficacy Chyawanprash, a…
Walk In Winter: In winter, the time from 7:00 AM to 9:00 AM is considered…
Does Maida Stick To Your Gut Lining: In this article, we debunk the common myth…
https://youtu.be/4NTKSfNf1TM?si=Y4xkEOKDUvqpIEZt The Disadvantages of Heating Packaged Milk Milk is a staple in many households and…
A recent study has revealed a growing mental health crisis among teenagers globally, with nearly…